Zydus Pharmaceuticals (USA) Inc. Initiates Class II Recall of Chlorpromazine Hydrochloride Tablets Due to Nitrosamine Impurity
Zydus Pharmaceuticals (USA) Inc. has initiated a Class II recall for Chlorpromazine Hydrochloride Tablets, USP, 100 mg, distributed nationwide. The recall, D-0637-2025, stems from CGMP deviations, specifically the presence of N-Nitroso Desmethyl Chlorpromazine exceeding acceptable intake limits. This event underscores persistent nitrosamine impurity challenges and necessitates immediate supply chain and regulatory review by industry stakeholders.
FDA Initiates Class II Recall for Zydus' Chlorpromazine Hydrochloride Tablets Amid CGMP Deviations
Zydus Pharmaceuticals (USA) Inc. has initiated a voluntary Class II recall for specific lots of Chlorpromazine Hydrochloride Tablets, USP, 100 mg. This critical regulatory action, identified as recall number D-0637-2025, was initiated on September 3, 2025, and remains ongoing. The primary reason for this recall is documented Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of N-Nitroso Desmethyl Chlorpromazine exceeding the recommended acceptable intake limit. This impurity poses a significant concern for patient safety, prompting the FDA's classification of this event as Class II, indicating that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The affected product, identified by NDC 16714-050-01, was distributed nationwide across the USA. Procurement directors must immediately verify their inventory against the identified affected lots: Z305456 (Exp Date 31-10-25), Z401156 (Exp Date 28-02-26), and Z407306 (Exp Date 30-11-26). Failure to do so could result in distribution of non-compliant product and subsequent regulatory penalties. Regulatory affairs heads should analyze this event to reinforce internal CGMP compliance, particularly concerning impurity profiles and nitrosamine risk assessments.
Unpacking the Chlorpromazine Hydrochloride Supply Chain: Zydus Lifesciences and Northstar Rx
The recalled Chlorpromazine Hydrochloride Tablets, USP, 100 mg, are part of a complex global supply chain. While Zydus Pharmaceuticals (USA) Inc. is the recalling firm, the product was manufactured by Zydus Lifesciences Ltd. in Baddi, India, and subsequently manufactured for Northstar Rx LLC, located in Memphis, TN 38141. This multi-entity arrangement underscores the intricate web of responsibilities within the pharmaceutical industry, where manufacturing, marketing, and distribution are often handled by distinct legal entities. The product is a human prescription drug, administered orally, with the generic name Chlorpromazine Hydrochloride and UNII 9WP59609J6, under application number ANDA213368. Other associated product NDCs include 16714-047, 16714-048, 16714-049, and 16714-051. For supply chain VPs, this event highlights the critical importance of robust due diligence on all partners, from API manufacturers to contract packagers and distributors. Understanding the full chain of custody and responsibility is paramount to mitigating risk. Business development executives considering partnerships with global manufacturers or private label arrangements must ensure clear contractual terms regarding quality control, regulatory compliance, and recall procedures, especially when manufacturing occurs in different geographical regions.
Mitigating Nitrosamine Impurity Risks: A Persistent Regulatory Challenge
The presence of N-Nitroso Desmethyl Chlorpromazine above acceptable intake limits, cited as a CGMP deviation, places this recall squarely within the broader industry challenge of nitrosamine impurities. Nitrosamines are a class of compounds known to be probable human carcinogens, and their detection in various drug products has led to widespread recalls and enhanced regulatory scrutiny globally over recent years. This specific impurity, N-Nitroso Desmethyl Chlorpromazine, indicates a potential issue with either the manufacturing process of the active pharmaceutical ingredient (API) or the finished drug product, or even the raw materials used. Regulatory affairs heads must recognize that this is not an isolated incident but part of an ongoing regulatory focus. Companies are expected to conduct thorough risk assessments for nitrosamine formation and implement appropriate control strategies, including process changes, enhanced testing, and supplier qualification. Procurement directors must demand comprehensive nitrosamine risk profiles and mitigation plans from all API suppliers, ensuring that acceptable intake limits are rigorously met. This event reinforces the need for continuous monitoring and adaptation to evolving regulatory expectations regarding genotoxic impurities.
Strategic Sourcing and Risk Management for Essential Medicines
Chlorpromazine Hydrochloride is a well-established antipsychotic medication, making its consistent availability crucial for patient treatment. The recall of this product by Zydus Pharmaceuticals (USA) Inc. due to a critical quality issue underscores the inherent vulnerabilities in pharmaceutical supply chains, particularly for essential medicines. While the provided intelligence does not name alternative suppliers, this situation necessitates immediate action from procurement directors and supply chain VPs to identify and qualify diversified sources for Chlorpromazine Hydrochloride. Over-reliance on a single manufacturer or a limited set of suppliers, especially those with recent compliance issues, introduces unacceptable levels of risk to product availability and patient care. Strategic considerations should include exploring manufacturers in different geographical regions to build supply chain resilience against localized disruptions or regulatory actions. The qualification process for new API suppliers can be lengthy, often spanning 12-24 months, requiring significant investment in audits, analytical testing, and regulatory submissions. Business development executives should evaluate opportunities for strategic partnerships or internal manufacturing capabilities to secure long-term supply and mitigate future risks associated with external supplier compliance or capacity constraints.